{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:51:06Z","timestamp":1785858666032,"version":"3.56.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1097\/01.mnh.0000174397.59100.89","type":"journal-article","created":{"date-parts":[[2005,7,26]],"date-time":"2005-07-26T06:29:14Z","timestamp":1122359354000},"page":"435-441","source":"Crossref","is-referenced-by-count":32,"title":["Antihypertensive, cardiovascular, and pleiotropic effects of angiotensin-receptor blockers"],"prefix":"10.1097","volume":"14","author":[{"given":"Cristina","family":"Sierra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"de la Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210205","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"R2-4-20210205","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-4-20210205","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"R4-4-20210205","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial \u2013 the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"R5-4-20210205","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"R6-4-20210205","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R7-4-20210205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"R8-4-20210205","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"R9-4-20210205","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"R10-4-20210205","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"R11-4-20210205","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Breener","year":"2001","journal-title":"N Engl J Med"},{"key":"R12-4-20210205","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"R13-4-20210205","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"R14-4-20210205","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"R15-4-20210205","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N Engl J Med"},{"key":"R17-4-20210205","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"R18-4-20210205","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"R19-4-20210205","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"R20-4-20210205","first-page":"1218","article-title":"Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stoke"},{"key":"R21-4-20210205","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/01.CIR.97.1.48","article-title":"Prognostic significance of serial changes in left ventricular mass in essential hypertension","volume":"97","author":"Verdecchia","year":"1998","journal-title":"Circulation"},{"key":"R22-4-20210205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"R23-4-20210205","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of left ventricular hypertrophy by losartan compared with atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"R24-4-20210205","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/01.CIR.101.16.1899","article-title":"Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease","volume":"101","author":"Sch\u00e4chinger","year":"2000","journal-title":"Circulation"},{"key":"R25-4-20210205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.CIR.104.2.191","article-title":"Prognostic significance of endothelial dysfunction in hypertensive patients","volume":"104","author":"Perticone","year":"2001","journal-title":"Circulation"},{"key":"R26-4-20210205","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1161\/01.CIR.101.14.1653","article-title":"Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan","volume":"101","author":"Schiffrin","year":"2000","journal-title":"Circulation"},{"key":"R27-4-20210205","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09674845.2003.11783698","article-title":"Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients","volume":"60","author":"Bragulat","year":"2003","journal-title":"Br J Biomed Sci"},{"key":"R28-4-20210205","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"R29-4-20210205","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1161\/hc3701.095949","article-title":"Circulating cell adhesion molecules and death in patients with coronary artery disease","volume":"104","author":"Blankenberg","year":"2001","journal-title":"Circulation"},{"key":"R30-4-20210205","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/01.CIR.103.3.448","article-title":"Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apo-E-deficient mice","volume":"103","author":"Weiss","year":"2001","journal-title":"Circulation"},{"key":"R31-4-20210205","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0735-1097(03)00846-5","article-title":"Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients","volume":"42","author":"Kon","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"R32-4-20210205","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1161\/01.CIR.0000140265.21608.8E","article-title":"Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation","volume":"110","author":"Fliser","year":"2004","journal-title":"Circulation"},{"key":"R33-4-20210205","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0002-9149(01)02340-2","article-title":"Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation)","volume":"89","author":"Rahman","year":"2002","journal-title":"Am J Cardiol"},{"key":"R34-4-20210205","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1210\/jc.2002-021836","article-title":"Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-\u03baB, in mononuclear cells of normal subjects: evidence of an antiinflammatory action","volume":"88","author":"Dandona","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R35-4-20210205","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004872-200105000-00013","article-title":"Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension","volume":"19","author":"Park","year":"2001","journal-title":"J Hypertens"},{"key":"R36-4-20210205","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1161\/01.CIR.0000095031.51492.C5","article-title":"Prognostic significance of small artery structure in hypertension","volume":"108","author":"Rizzoni","year":"2003","journal-title":"Circulation"},{"key":"R37-4-20210205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.HYP.0000153308.91043.97","article-title":"Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus","volume":"45","author":"Rizzoni","year":"2005","journal-title":"Hypertension"},{"key":"R38-4-20210205","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.CIR.0000137118.47943.5C","article-title":"Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis","volume":"110","author":"Ciulla","year":"2004","journal-title":"Circulation"},{"key":"R39-4-20210205","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/01.HYP.0000125726.92964.ab","article-title":"Adverse prognostic significance of new diabetes in treated hypertensive subjects","volume":"43","author":"Verdecchia","year":"2004","journal-title":"Hypertension"},{"key":"R40-4-20210205","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200003303421301","article-title":"Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study","volume":"342","author":"Gress","year":"2000","journal-title":"N Engl J Med"},{"key":"R41-4-20210205","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/00004872-200412000-00003","article-title":"Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system","volume":"22","author":"Kurtz","year":"2004","journal-title":"J Hypertens"},{"key":"R42-4-20210205","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000127955.36250.65","article-title":"Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-\u03b3 activity","volume":"109","author":"Schupp","year":"2004","journal-title":"Circulation"}],"container-title":["Current Opinion in Nephrology &amp; Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.mnh.0000174397.59100.89","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:56:12Z","timestamp":1785855372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00041552-200509000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mnh.0000174397.59100.89","relation":{},"ISSN":["1062-4821"],"issn-type":[{"value":"1062-4821","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}